{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:19Z","timestamp":1790775679281,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005869","name":"University of Fribourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005869","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["FNS-31003A_163432"],"award-info":[{"award-number":["FNS-31003A_163432"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["PNR72-40AR40_173686"],"award-info":[{"award-number":["PNR72-40AR40_173686"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy of the recently launched \u03b2-lactam\/\u03b2-lactamase inhibitor combinations ceftazidime\/avibactam and ceftolozane\/tazobactam against ESBL-producing Escherichia coli and Pseudomonas aeruginosa strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A series of ESBL-encoding genes (blaTEM, blaSHV, blaCTX-M, blaVEB, blaPER, blaGES and blaBEL) was cloned and expressed in E. coli or P. aeruginosa recipient strains. Cultures of E. coli TOP10 harbouring recombinant plasmids and therefore producing the different ESBLs tested were grown in order to perform measurements of catalytic activities, using benzylpenicillin, ceftazidime and ceftolozane as substrates. IC50s were additionally determined for clavulanic acid, tazobactam and avibactam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We showed here an overall better activity of ceftazidime\/avibactam compared with ceftolozane\/tazobactam toward ESBL-producing E. coli and P. aeruginosa. Several ESBLs of the GES, PER and BEL types conferred resistance to ceftolozane\/tazobactam in E. coli and P. aeruginosa. For GES-6 and PER-1 producers, resistance to ceftolozane\/tazobactam could be explained by a high hydrolysis of ceftolozane and a low activity of tazobactam as an inhibitor. On the other hand, PER-producing P. aeruginosa also exhibited resistance to ceftazidime\/avibactam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Altogether, the results show that the ESBL PER-1, which is widespread worldwide, may be a source of resistance to both ceftolozane\/tazobactam and ceftazidime\/avibactam. Excellent activity of ceftazidime\/avibactam was highlighted for both ESBL-producing E. coli and ESBL-producing P. aeruginosa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz149","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T16:14:28Z","timestamp":1553098468000},"page":"1934-1939","source":"Crossref","is-referenced-by-count":108,"title":["ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa"],"prefix":"10.1093","volume":"74","author":[{"given":"Jos\u00e9-Manuel","family":"Ortiz de la Rosa","sequence":"first","affiliation":[{"name":"Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[{"name":"Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland"},{"name":"Swiss National Reference Centre for Emerging Antibiotic Resistance, Fribourg, Switzerland"},{"name":"INSERM European Unit (LEA), IAME, Paris, France"},{"name":"University of Lausanne and University Hospital Centre, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poirel","sequence":"additional","affiliation":[{"name":"Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland"},{"name":"Swiss National Reference Centre for Emerging Antibiotic Resistance, Fribourg, Switzerland"},{"name":"INSERM European Unit (LEA), IAME, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"2019091012085337700_dkz149-B1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","article-title":"Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology","volume":"45","author":"Potron","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019091012085337700_dkz149-B2","doi-asserted-by":"crossref","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2019091012085337700_dkz149-B4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinthera.2016.01.018","article-title":"Ceftazidime\u2013avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms","volume":"38","author":"Sharma","year":"2016","journal-title":"Clin Ther"},{"key":"2019091012085337700_dkz149-B5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085337700_dkz149-B6","doi-asserted-by":"crossref","first-page":"e00528","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime\u2013avibactam: unique antibiotic-resistant phenotypes emerge from \u03b2-lactamase protein engineering","volume":"8","author":"Barnes","year":"2017","journal-title":"MBio"},{"key":"2019091012085337700_dkz149-B7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019091012085337700_dkz149-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019091012085337700_dkz149-B9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1469-0691.2007.01861.x","article-title":"Minor extended-spectrum \u03b2-lactamases","volume":"14","author":"Naas","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2019091012085337700_dkz149-B10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2019091012085337700_dkz149-B11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/AAC.44.3.622-632.2000","article-title":"Biochemical sequence analyses of GES-1, a novel class A extended-spectrum \u03b2-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae","volume":"44","author":"Poirel","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B12","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/AAC.45.9.2598-2603.2001","article-title":"GES-2, a class A \u03b2-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem","volume":"45","author":"Poirel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B13","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.00033-09","article-title":"Integron mobilization unit as a source of mobility of antibiotic resistance genes","volume":"53","author":"Poirel","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B14","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.04450-14","article-title":"In vitro prediction of the evolution of GES-1 \u03b2-lactamase hydrolytic activity","volume":"59","author":"Bontron","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B15","first-page":"209","article-title":"Novel GES\/IBC extended-spectrum \u03b2-lactamase variants with carbapenemase activity in clinical enterobacteria","volume":"234","author":"Vourli","year":"2004","journal-title":"FEMS Microbiol Lett"},{"key":"2019091012085337700_dkz149-B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/dkx337","article-title":"Unravelling the genome of a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 reveals an integrative conjugative element housing a blaGES-6 carbapenemase","volume":"73","author":"Botelho","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085337700_dkz149-B17","doi-asserted-by":"crossref","first-page":"e01809","DOI":"10.1128\/AAC.01809-18","article-title":"Acquisition of extended-spectrum \u03b2-lactamase GES-6 leading to resistance to ceftolozane\u2013tazobactam combination in Pseudomonas aeruginosa","volume":"63","author":"Poirel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0378-1119(94)90237-2","article-title":"Construction of improved Escherichia\u2013Pseudomonas shuttle vectors derived from pUC18\/19 and sequence of the region required for their replication in Pseudomonas aeruginosa","volume":"148","author":"West","year":"1994","journal-title":"Gene"},{"key":"2019091012085337700_dkz149-B19","year":"2018"},{"key":"2019091012085337700_dkz149-B20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085337700_dkz149-B21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2019091012085337700_dkz149-B22","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/AAC.02151-13","article-title":"Impact of renal function on the pharmacokinetics and safety of ceftolozane\u2013tazobactam","volume":"58","author":"Wooley","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085337700_dkz149-B23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-018-0705-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of ceftazidime\u2013avibactam combination: a model-informed strategy for its clinical development","volume":"58","author":"Sy","year":"2019","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz149\/28505989\/dkz149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/7\/1934\/28851735\/dkz149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T11:36:50Z","timestamp":1569238610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/7\/1934\/5477399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,23]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz149","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,4,23]]}}}